Ophthotech Corp. (NASDAQ:OPHT) – Analysts at Leerink Swann decreased their FY2016 EPS estimates for Ophthotech Corp. in a research note issued on Tuesday. Leerink Swann analyst J. Schwartz now expects that the firm will post earnings of ($5.34) per share for the year, down from their previous estimate of ($5.28). Leerink Swann has a “Positive” rating and a $72.00 price target on the stock. Leerink Swann also issued estimates for Ophthotech Corp.’s Q4 2016 earnings at ($1.76) EPS, FY2017 earnings at ($4.86) EPS and FY2018 earnings at ($2.54) EPS.

Other analysts have also recently issued research reports about the stock. Citigroup Inc. set a $92.00 price target on shares of Ophthotech Corp. and gave the company a “buy” rating in a research report on Sunday, October 30th. Cowen and Company set a $60.00 price target on shares of Ophthotech Corp. and gave the company a “buy” rating in a research report on Saturday, October 1st. Barclays PLC reaffirmed a “buy” rating on shares of Ophthotech Corp. in a research report on Tuesday, July 19th. Chardan Capital reaffirmed a “buy” rating and set a $200.00 price target on shares of Ophthotech Corp. in a research report on Monday, October 31st. Finally, Goldman Sachs Group Inc. reaffirmed a “sell” rating and set a $45.00 price target on shares of Ophthotech Corp. in a research report on Wednesday, August 10th. Two research analysts have rated the stock with a sell rating and nine have given a buy rating to the company’s stock. Ophthotech Corp. currently has a consensus rating of “Buy” and an average target price of $88.36.

Earnings History and Estimates for Ophthotech Corp. (NASDAQ:OPHT)

Ophthotech Corp. (NASDAQ:OPHT) opened at 36.41 on Friday. Ophthotech Corp. has a one year low of $29.85 and a one year high of $80.00. The company’s market cap is $1.28 billion. The stock has a 50 day moving average price of $40.41 and a 200 day moving average price of $50.43.

Ophthotech Corp. (NASDAQ:OPHT) last announced its quarterly earnings data on Tuesday, November 8th. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.64) by $0.07. The company earned $1.67 million during the quarter, compared to the consensus estimate of $6.20 million. Ophthotech Corp. had a negative net margin of 323.19% and a negative return on equity of 916.07%.

Large investors have recently bought and sold shares of the company. BNP Paribas Arbitrage SA raised its stake in Ophthotech Corp. by 114.4% in the third quarter. BNP Paribas Arbitrage SA now owns 2,590 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 1,382 shares in the last quarter. Teacher Retirement System of Texas raised its stake in Ophthotech Corp. by 18.5% in the second quarter. Teacher Retirement System of Texas now owns 3,582 shares of the biopharmaceutical company’s stock worth $183,000 after buying an additional 559 shares in the last quarter. Great West Life Assurance Co. Can raised its stake in Ophthotech Corp. by 66.0% in the third quarter. Great West Life Assurance Co. Can now owns 3,651 shares of the biopharmaceutical company’s stock worth $168,000 after buying an additional 1,451 shares in the last quarter. BlackRock Inc. raised its stake in Ophthotech Corp. by 138.0% in the second quarter. BlackRock Inc. now owns 3,965 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 2,299 shares in the last quarter. Finally, Emerald Acquisition Ltd. acquired a new stake in Ophthotech Corp. during the second quarter worth $227,000. Institutional investors own 92.83% of the company’s stock.

In related news, President Samir Chandrakant Patel sold 20,000 shares of the company’s stock in a transaction dated Thursday, September 29th. The shares were sold at an average price of $55.17, for a total value of $1,103,400.00. Following the sale, the president now owns 24,239 shares in the company, valued at approximately $1,337,265.63. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO David R. Guyer sold 22,060 shares of the company’s stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $44.37, for a total transaction of $978,802.20. Following the completion of the sale, the chief executive officer now owns 24,541 shares in the company, valued at approximately $1,088,884.17. The disclosure for this sale can be found here. Insiders own 2.00% of the company’s stock.

Ophthotech Corp. Company Profile

Ophthotech Corporation is a biopharmaceutical company. The Company specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (AMD). Its advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs.

5 Day Chart for NASDAQ:OPHT

Receive News & Stock Ratings for Ophthotech Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech Corp. and related stocks with our FREE daily email newsletter.